CN Patent

CN110913840A — 包含3-氟-4-[7-甲氧基-3-甲基-8-(1-甲基-1H-吡唑-4-基)-2-氧代-2,3-二氢-咪唑并[4,5-c]喹啉-1-基]-苄腈的药物制剂

Assigned to Merck Patent GmbH · Expires 2020-03-24 · 6y expired

What this patent protects

本发明涉及3‑氟‑4‑[7‑甲氧基‑3‑甲基‑8‑(1‑甲基‑1H‑吡唑‑4‑基)‑2‑氧代‑2,3‑二氢‑咪唑并[4,5‑c]喹啉‑1‑基]‑苄腈的固体药物制剂、其制备方法及其医学用途。

USPTO Abstract

本发明涉及3‑氟‑4‑[7‑甲氧基‑3‑甲基‑8‑(1‑甲基‑1H‑吡唑‑4‑基)‑2‑氧代‑2,3‑二氢‑咪唑并[4,5‑c]喹啉‑1‑基]‑苄腈的固体药物制剂、其制备方法及其医学用途。

Drugs covered by this patent

paltusotine-hydrochloride (PALTUSOTINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN110913840A
Jurisdiction: CN
Classification: —
Expires: 2020-03-24
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.